Office of Research & Development

For Researchers and Research Partners MVP map

Announcements:

Gamma Test of the Million Veteran Program
Request for Applications
NOTE: This is available on the intranet only. If you have intranet access copy and paste this URL into you browser: http://vaww.genisis.med.va.gov/rfa/mvp/
LOI due February 15, 2017

Thank you for your submissions! The submission period for LOIs is now closed. Additional details will be available soon.

A Request for Applications (RFA) has been announced for a gamma test of MVP's scientific computing infrastructure for data-use projects. All VA investigators from all VA service areas are welcome to submit an LOI. More details can be found at: http://vaww.genisis.med.va.gov/rfa/mvp/ (This is available on the intranet only. If you have intranet access copy and paste this URL into you browser.).

Please note that Letters of Intent (LOIs) are due February 15, 2017. For any questions regarding this RFA, please e-mail MVPLOI@va.gov.



The Million Veteran Program (MVP) was conceived and implemented to promote genomic discoveries and help bring personalized medicine to the forefront of VA health care. As of August 2016, MVP has enrolled over 500,000 participants. The program is entering the next phase of making these data available, first to VA investigators with plans for expanding in the future to non-VA investigators, for genomic and epidemiological studies that will inform health care delivery.

At this time, we are conducting alpha and beta tests of the scientific computing infrastructure. Please find details below on the current projects:

Beta Projects (Data use studies)

Genetic Vulnerability of Sustained Multi-substance Use in MVP

Dr. Daniel Federman and Dr. Amy Justice at the VA Connecticut Healthcare System and Dr. Henry Kranzler at the Philadelphia VA Medical Center will examine genetic risk factors for chronic use of alcohol, tobacco, and opioids—and the dangerous use of all three together.

Genetics of Cardio-Metabolic Diseases in the VA Population

Dr. Philip Tsao at the VA Palo Alto Health Care System and Dr. Kyong-Mi Chang at the Philadelphia VA Medical Center will lead a study to explore the role of genetics in obesity, diabetes, and abnormal lipid levels (namely, cholesterol and triglycerides), as drivers of heart disease. This project will help more thoroughly understand underlying causes of cardiometabolic disease and develop new therapies that are safe, effective, and personalized.

Pharmacogenomics of Risk Factors and Therapies Outcomes of Kidney Disease

Dr. Adriana Hung at the VA Tennessee Valley Healthcare System will lead a study focusing on how genes affect the risk and progression of kidney disease, one goal is to examine how patients with diabetes—who often develop kidney problems—respond differently to the drug metformin, the standard first-line treatment for diabetes, based on their genetic profile. The project will also look at the genetics of hypertension, a major risk factor for kidney disease.

Cardiovascular Disease Risk Factors, Prevalent Cardiovascular Disease and Genetics in the Million Veteran Program

Dr. Peter Wilson at the Atlanta VA Medical Center and Dr. Kelly Cho at the Boston VA Healthcare System will lead an effort probing the genes that influence how obesity and lipid levels affect heart risk. Using MVP data, this study will also look at whether these genetic factors differ among African Americans and Hispanics.

Genetic Risk for AMD in Diverse Veteran Populations

Drs. Eric Konicki and Neal Peachey at the Cleveland VA Medical Center and Dr. Steven Fliesler at the VA Western New York Healthcare System at Buffalo will lead a project to determine whether Age-related Macular Degeneration (AMD) susceptibility genes identified to date in Caucasian-Americans are shared in African-Americans. This question is important because the recent advances in AMD genetics are being used to develop new therapeutics to slow or halt vision loss in the more prevalent forms of AMD.

Alpha Projects (Re-contact studies)

Gulf War Illness (GWI) Risk Factors

Dr. Drew Helmer at the VA New Jersey Health Care System and Dr. Dawn Provenzale at the VA Cooperative Studies Epidemiology Center (Durham) will examine the genes that influence the development of Gulf War Illness (GWI) in Gulf War Era Veterans. Using MVP data, their team will compare "case" patients with healthy "controls" and also look at the relationships between genetic variations, self-reported Gulf War environmental exposures, and susceptibility to GWI.

Posttraumatic Stress Disorder (PTSD) Risk Factors

Dr. Murray Stein at the San Diego VA Medical Center and Dr. Joel Gelernter of the VA Connecticut Healthcare System will lead an effort probing the genes that influence the development of PTSD in combat exposed Veterans. Using MVP data, their team will conduct one of the largest genetic studies of PTSD and will help to identify genes that improve understanding of PTSD neurobiology.

Functional Disability in Schizophrenia and Bipolar Illness

Dr. Philip Harvey at the Miami VA Medical Center leads a multicenter observational (case-control) study to examine genetic risk factors for developing schizophrenia (SZ) or bipolar disorder (BP) and the functional disability and cognitive impairment that accompany these conditions. This study will compare "case" patients with SZ or BP recruited for the study with healthy "controls" obtained from MVP.

Text size: + -

Contact MVP

Contact the MVP Information Center toll-free at 866-441-6075.

Downloads

MVP Insider:A Newsletter for Million Veteran Program Participants

MVP Insider: A Newsletter for Million Veteran Program Participants
- Issue 4, Winter 2016-2017
- Issue 3, Fall 2015
- Issue 2, Summer 2014
- Issue 1, Summer 2013


Questions about the R&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.